Mark Trocha, DVM

** ***** ******, ****#***, Charlestown, Massachusetts 02129

603-***-**** [C] adtpvo@r.postjobfree.com

https://www.linkedin.com/in/mark-trocha

PRINCIPAL SCIENTIST// MANAGER

IN VIVO PHARMACOLGY

Summary

Highly skilled scientist with over 30 years of experience in research and drug discovery in both academia and the pharmaceutical industry. Solid, hands-on experience in multiple areas essential for drug discovery and drug development. Strong skills in project management and team leadership. Recognized as a high energy performer with excellent communication skills. Proven ability to rapidly set up various animal models and train personnel. Honored as Keynote Speaker for Teaching Session at Sixth World Congress on Inflammation, Vancouver.

PROFESSIONAL EXPERIENCE

GLAXOSMITHKLINE// TEMPERO PHARMACEUTICALS

2010- 2022

INVESTIGATOR/ IN VIVO PHARMACOLOGY

IMMUNO-INFLAMMATION; GENOMIC IMMUNOLOGY

Disease modeling

“Humanized “Mice –Autoimmunity//Tregs FOXP3

In-vivo pharmacology PK/DMPK

Regulation of Th17 cytokines in naïve T cell Differentiation

FACS Analysis

Inflammation and Autoimmunity (EAE)

IBD and Metabolic diseases

CIA Mouse Model

Intra-Dermal Mouse Inflammation Model

Psoriasis Skin like Inflammation: Imiquimod Mouse Model

RESOLVYX PHARMACEUTICALS

2006-2010

SCIENTIST IN VIVO PHARMACOLOGY

Developed and implemented a variety of rodent models for human diseases.

The following animal models of human disease were established and used for drug screening purposes: Experimental Autoimmune Encephalomyelitis, Asthma, DTH, Air Pouch Model, IBD, and Arthritis Model.

Provided scientific leadership for in-vivo validation and preclinical development of lead compounds for the treatment of respiratory diseases.

Developed and utilized appropriate in vivo/ex-vivo models for asthma and IBD.

Managed and trained junior scientific staff on all aspects of laboratory operations and procedures.

Held regulatory responsibilities, including writing of preclinical sections for Due Diligence documents.

Analyzed and presented data to R and D committee to ensure all were kept abreast of project progress.

Served as a Member of the Resolvyx IACUC team.

NITROMED, INC

1997-2006

SCIENTIST IN VIVO PHARMACOLOGY

Participated in research on interactive drug discovery with a focus on the identification and development of therapeutics for targeted delivery of nitric oxide

Managed the development and implementation of animal models for the evaluation of drug candidates in the areas of inflammation, cardiovascular, hypertension, restenosis, sexual dysfunction, gastro-intestinal, cerebral ischemia, and stroke

Responsible for Setting CAT/LAB- CT, MRI, Fluoroscopy

Gained expertise in the establishment of animal models of human disease.

Responsible for administration of the onsite animal care facility and IACUC

Adhered to standard operating procedures and ensured compliance with all regulations

MASSACHUSETTS GENERAL HOSPITAL

DEPARTMENT OF RADIOLOGY, HARVARD MEDICAL SCHOOL

1990-1997

SENIOR RESEARCH TECHNOLOGIST

Responsible for developing animal models of cerebral ischemia and restenosis

Developed animal tumor models: liver, kidney and prostate

Applied Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) to study in vivo animal models of cerebral ischemia

Screened contrast agents for Lymphography and Blood Pool (MRI, CT)

Performed image segmentation and quantitative image analysis on CT and MRI functional data

Primary areas of expertise include:

In-vivo pharmacology

Cardiovascular

Inflammation

Pharmacokinetics/Pharmacodynamics

Imaging/ MRI, CT, PET, Fluoroscopy

Ischemia /stroke

Pain

Autoimmunity (EAE)

Autoimmunity (EAE)

Arthritis

Asthma

Dermatitis/Psoriasis

IBD and Metabolic Diseases

Oncology

Sexual dysfunction

Veterinary expertise

RELATED LAB EXPERIENCE:

Animal surgery

Data Analysis and Presentation

Management of Animal Facility

Infrared Thermography

RNA extraction TagMan

FACS

Computer Skills

Microsoft Office

Prism

Adobe Photoshop

NIH-Image

Image J

DIP-Station

Mac OS

Emka

Education

Doctor of Veterinary Medicine, Agriculture Technical Academia, Olsztyn, Poland

Publications

1.Ellis JL, Augustyniak ME, Cochran ED, Earl RA, Garvey DS, Gordon LJ, Janero DR, Khanapure SP, Letts LG, Melim TL, Murty MG, Schwalb DJ, Shumway MJ, Selig WM, Trocha AM, Young DV, Zemtseva IS. NMI-1182, a gastroprotective cyclooxygenase inhibiting nitric oxide donor. Inflamm Pharmacology 12: 521-534, 2005.

2.Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murthy MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR. 3-[4-(Methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 (COX-2) selective inhibitor: synthesis and biological evaluation. J Med Chem 48: 3930-3934, 2005.

3.Lin C-E, Garvey DS, Janero DR, Letts LG, Marek P, Richardson SK, Shumway MJ, Trocha AM, Young DV. The combination of paclitaxel and nitric oxide as a potential novel treatment for the prevention of restenosis. J Med Chem 47: 2276-2282, 2004.

4.Ranatunge RR, Augustyniak M, Bandarage UK, Earl RA, Ellis JL, Garvey DS, Janero DR, Letts LG, Martino A, Murty MG, Richardson SK, Schroeder JD, Shumway MJ, Tam SW, Trocha AM., Young DV. Synthesis and selective cyclooxygenase-2 (Cox-2) inhibitory activity of a series of novel nitric oxide donor containing pyrazoles. J Med Chem 47: 2180-2193, 2004.

5.Khanapure SP, Garvey DS, Young DV, Ezawa M, Earl RA, Gaston RD, Fang X, Murty M, Martino A, Shumway M, Trocha AM, Marek P, Tam SW, Janero DR, Letts LG. Synthesis and Structure-Activity Relationship (SAR) of novel, highly potent metharyl and methcycloalkyl cyclooxygenase (COX-2) selective inhibitors. J Med Chem 46: 5484-5504, 2003.

6.Saenz de Tejada I, Garvey DS, Schroeder JD, Shelekhin T, Letts LG, Fernandez A, Cuevas B, Gabancho S, Martinez V, Angulo J, Trocha AM, Marek P, Cuevas P, Tam SW. Design and evaluation of nitrosylated a-adrenergic receptor antagonists as potential agents for the treatment of impotence. J Pharmacol Exp Ther 290: 121-128, 1999.

7.Wolf GL, Rogowska J, Bessin G, Trocha M, Whiteman K, Wolf D, Shore MT. Visualizing renal anatomy and function with 1-10,000nm radiocontrast agents. Academic Radiology 5:127-130, 1998.

8. Lo EH, Rogowska J, Bogorodzki P, Trocha M, Matsumoto K, Saffran BN, Wolf GL. Temporal correlation analysis of penumbral dynamics in focal cerebral ischemia. J Cereb Blood Flow Metab 16:60-68, 1996.

9. Lo EH. Hara H, Rogowska J, Trocha M, Pierce AR, Huang PL, Fishman MC, Wolf GL, Moskowitz MA. Temporal correlation mapping analysis of the hemodynamic penumbra in mutant mice deficient in endothelial nitric oxide synthase gene expression. Stroke 27(8):1381-1385, 1996.

Abstracts

1.Schwalb DJ, Augustyniak ME, Earl RA, Ellis JL, Garvey DS, Gordon LJ, Janero D R, Khanapure SP, Letts LG, Melim TL, Shumway MJ, Selig WM, Trocha AM, Young DV, Zemtseva IS. NMI-1182, a gastroprotective cyclooxygenase inhibiting nitric oxide donor (CINOD): anti-inflammatory activity in the rat. 12th International Conference of the Inflammation Research Association. Sagamore, NY. October 3-7 (2004) A114.

2.Ranatunge RR, Augustyniak M, Dhawan V, Ellis JL, Garvey DS, David Janero DR, Letts LG, Richardson SK, Shumway MJ, Trocha AM, Young DV, Zemtseva IS. The synthesis and anti-inflammatory activity of a series of N-substituted glycolamides of naproxen: nitric oxide donor contains naproxen prodrugs. 228th ACS National Meeting, Philapdelphia, PA, August 22 -26 (2004) MEDI-247.

3.Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murthy MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR. A potent and highly selective cyclooxygenase-2 (COX-2) inhibitor from a novel pyridyl metharyl series. 228th ACS National Meeting, Philapdelphia, PA, August 22 -26, (2004) MEDI-243.

4.Shumway MJ, Augustyniak ME, Earl RA, Ellis JL, Garvey DS, Gordon LG, Janero DR, Khanapure SP, Letts LG, Melim TL, Schwalb DJ, Selig WM, Trocha AM, Young DV, Zemtseva IS. The novel cyclooxygenase inhibiting nitric oxide donor (CINOD), NMI-1182, attenuates inflammation in the rat air pouch model. FASEB Journal, Vol. 18, No. 4-5, 2004 PP. Abst. 408.10. FASEB Meeting on Experimental Biology, Washington D.C. April 17-21 (2004) A5875.

5.Trocha AM, Augustyniak ME, Earl RA, Ellis JL, Garvey DS, Janero DR, Khanapure SP, Letts LG, Schwalb DJ, Selig WM, Shumway MJ, Zemtseva IS. NMI-1182: A novel, gastroprotective, orally bioavailable cyclooxygenase inhibitory nitric oxide donor (CINOD) in the rat paw edema inflammation model. FASEB Meeting on Experimental Biology, Washington D.C. April 17-21 (2004) A5799.

6.Trocha AM, Shumway M, Augustyniak D, Young D, Janero D, Letts G. Six-day rat carrageenan air-pouch model: development and response to anti-inflammatory COX-2 selective inhibitors. Sixth World Congress on Inflammation, Vancouver, August 2-6,2003.

7.Augustyniak M, Bandarage UK, Earl RA, Fang X, Garvey DS, Janero DR, Khanapure SP, Letts LG, Martino AM, Murty MM, Ranatunge RR, Schroeder JD, Shumway MJ, Trocha AM, Young DV, Zemtseva I. Synthesis and structure-activity-relationships of a series of novel nitric oxide donor containing selective cyclooxygenase-2 inhibitors. Sixth World Congress on Inflammation, Vancouver August 2-6, 2003.

8.Janero DR, Augustyniak M, Cochran E, Earl R, Ezawa M, Fang F, Garvey DS, Gaston R, Khanapure S, Letts GL, Marek P, Ranatunge R, Shumway M, Stevenson C, Trocha M, Wey S-J,Young D. Novel nitrated cyclooxygenase-2 (COX-2) selective inhibitors: improved anti-inflammatory medicines with gastroprotective properties. Experimental Biology Meeting, San Diego. FASEB J. 17:A1344, 2003.

9.Shimizu-Sasamata M, Kano T, Pierce AR, Rogowska J, Trocha M, Shore MT, Hara H, Moskowitz MA, Lo EH. Early functional computed tomography predicts later brain damage after focal ischemia in rats. Proceedings of the 22nd International Joint Conference on Stroke and Cerebral Circulation, Anaheim, CA, Feb. 6-8, 1997.

10.Rogowska J, Lo EH, Hara H, Trocha M, Pierce AR, Huang P.L, Fishman M, Wolf GL, Moskowitz MA. In vivo functional imaging of the hemodynamic penumbra in eNOS knockout mice. XI Annual Meeting of the American Assoc. of Pharmaceutical Scientists, Seattle, Oct 27-31, 1996.

11.Marek P, Trocha M, Wu T, Jablonski T, Earl R, Bandarage R, Richardson S. Infrared Thermography for detection of changes in hemodynamics status of labia and clitoris after topical application of nitric oxide donor. ASBMB/ASPET, 2000.

12.Lo EH, Kano T, Shimizu-Sasamata M, Hara H, Rogowska J, Trocha M, Pierce AR, Huang PL, Fishman M, Wolf GL, Moskowitz MA. Hemodynamic and neuromodulatory effects of NOS gene deletion: In vivo functional imaging and microdialysis studies in knockout mice. Proceedings of the 26th Annual Meeting of the Society for Neuroscience, Washington, D.C, Nov. 16-21, 1996.

13.Lo EH, Rogowska J, Bogorodzki P, Trocha M, Matsumoto K, Saffran BN, Wolf GL. A New method for imaging the penumbra in focal ischemia: Temporal Evolution and Correlation with Histologic Outcome. (J Cereb Blood Flow Metab 15: s324, 1995). 17th International Symposium on Cerebral Blood Flow and Metabolism, Koln, Germany, 1995.

14.Rogowska J, Lo EH, Bogorodzki P, Trocha M, Wolf GL. New temporal correlation techniques for imaging the penumbra in stroke. X Annual Meeting of the American Assoc. of Pharmaceutical Scientists, Miami Beach, Nov. 5-9, 1995.

Contact this candidate